Entering text into the input field will update the search result below

Early-stage study underway assessing Palatin's lead candidate PL-8177

Feb. 05, 2018 11:07 AM ETPalatin Technologies, Inc. (PTN) StockBy: Douglas W. House, SA News Editor1 Comment
  • Dosing has commenced in a Phase 1 clinical trial evaluating the safety and tolerability of Palatin Technologies' (NYSE:PTN) lead candidate PL-8177 in healthy volunteers. Top-line data are expected in Q3.
  • PL-8177 is a selective melanocortin receptor 1 (MC1r) agonist peptide. In other words, it is a modulator of the melanocortin system which plays a key role in appetite and energy expenditure. It is being developed for the treatment of ulcerative colitis and other inflammatory bowel disorders.
  • Previously: Palatin to start clinical development of UC candidate PL-8177; shares up 6% premarket (Jan. 3)

Recommended For You

About PTN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PTN--
Palatin Technologies, Inc.